Oragenics

Contributing Author

Recent Articles by Oragenics

Aug-11	Oragenics Q2 2025 Shareholder Update OGEN GlobeNewswire
Jul-31	Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial OGEN GlobeNewswire
Jul-16	Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development OGEN +5.97% GlobeNewswire
Jul-02	Oragenics Completes Approximately $16.5 Million Offering OGEN -7.10% OGEN +6.25% GlobeNewswire
Jul-01	Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants OGEN -59.42% GlobeNewswire
Jun-10	Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium OGEN GlobeNewswire
May-28	Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split OGEN -27.76% GlobeNewswire
May-13	Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia OGEN +8.89% GlobeNewswire
May-12	Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision OGEN +6.76% GlobeNewswire